Company / Operating Income
NewAmsterdam Pharma Co N.V. Operating Income History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$225.7M
FY2025
5-year range
-$225.7M / -$3.6M
FY2021-FY2025
Trend
-28.0%
vs FY2024
Sector context
#153 of 204
Health Care
What the data says
NewAmsterdam Pharma Co N.V.'s operating income of -$226M is lower than 75% of companies in the Health Care sector (FY2025). Operating Income has fluctuated over the past 5 years, ranging from -$226M in FY2025 to -$4M in FY2022.
Based on SEC 10-K filings.
-$226M in FY2025.
Declined from -$183M to -$226M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 204This company -$225.7M Sector average $107.7M
▼
-309.5% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 28.0% year-over-year.
- Ranks #153 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$225.7M | -28.0% |
| FY2024 | -$176.3M | +3.6% |
| FY2023 | -$183.0M | -5043.9% |
| FY2022 | -$3.6M | +89.8% |
| FY2021 | -$35.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026